Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 14, 2007. The report details a specific corporate action regarding a share repurchase authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 950,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,309.5 pence per share.
- Treasury Holdings: 314,939,158 shares (representing 5.52% of total voting rights).
- Shares in Issue: 5,705,749,490 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 950,000 shares on June 14, 2007. These shares are intended to be held in Treasury. Consequently, the total number of shares held in Treasury increased to 314,939,158.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,705,749,490) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (314,939,158) and its impact on the total voting rights percentage (5.52%).
- Note that this filing does not contain financial results; investors should refer to Form 20-F or other periodic reports for revenue and earnings data.